Antibiotic Resistance Dynamics in Acinetobacter Baumannii Infections
Summary
Acinetobacter baumannii has emerged as a formidable opportunistic pathogen in hospital settings, notable for its capacity to acquire resistance to nearly all classes of antimicrobial agents. Its role in ventilator-associated pneumonia, bloodstream infections and wound infections has intensified clinical challenges, especially in intensive care units. Resistance dynamics in A. baumannii are driven by a combination of chromosomal mutations, acquisition of mobile genetic elements bearing β-lactamase genes and upregulation of efflux pumps. Carbapenems once represented first-line therapy, but the global proliferation of carbapenem-hydrolysing oxacillinases has eroded their efficacy, leading to renewed reliance on polymyxins and the glycylcycline tigecycline. Simultaneously, A. baumannii’s ability to form robust biofilms on medical devices and hospital surfaces facilitates persistence and cross-transmission. Surveillance data indicate that multidrug-resistant and extensively drug-resistant lineages are now endemic in many regions, with particular acceleration in intensive care settings. The interplay of local antimicrobial stewardship practices, infection control measures and the genetic adaptability of A. baumannii defines regional and global resistance trajectories. Understanding these dynamics is essential to inform therapeutic strategies, guide development of novel antimicrobials and reinforce infection prevention protocols.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Antibiotic Resistance Dynamics in Acinetobacter Baumannii Infections publication trend
The graph below shows the total number of articles in antibiotic resistance dynamics in acinetobacter baumannii infections across all publications each year (not limited to Nature Index journals).
Technical terms
Carbapenems: A class of β-lactam antibiotics once highly effective against A. baumannii, now compromised by carbapenem-hydrolysing enzymes.
Multidrug-resistant (MDR): Refers to bacteria non-susceptible to at least three classes of antimicrobial agents.
Extensively drug-resistant (XDR): Denotes MDR strains also resistant to last-resort agents such as carbapenems and polymyxins.
β-lactamases: Enzymes that hydrolyse β-lactam antibiotics; includes oxacillinases (OXAs), metallo-β-lactamases (MBLs) and extended-spectrum β-lactamases (ESBLs).
OXA-type carbapenemase: A class D β-lactamase capable of degrading carbapenem antibiotics, often encoded by blaOXA genes.
Metallo-β-lactamases (MBLs): Zinc-dependent enzymes that hydrolyse a broad range of β-lactams, including carbapenems.
Extended-spectrum β-lactamases (ESBLs): Enzymes that confer resistance to penicillins and cephalosporins by hydrolysing their β-lactam ring.
Biofilm: A structured community of bacteria encased in a self-produced matrix, enhancing survival on surfaces and reducing antibiotic penetration.
References
- Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerging Microbes & Infections (2018).
- A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Annals of Clinical Microbiology and Antimicrobials (2019).
- Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant Acinetobacter baumannii isolated from burn wound infections in Iran. Antimicrobial Resistance & Infection Control (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.